Canopy Growth reports Q2 EPS (C$1.48) vs. (C$4.33) last year

Reports Q2 revenue C$73.96M vs. $82.08M last year. David Klein, CEO, said, “We delivered a solid second quarter led by strong growth across our Storz & Bickel, Canadian medical, and European cannabis businesses and we are well positioned to accelerate momentum in the second half of our fiscal year. In addition, we remain highly optimistic about the momentum building within Canopy USA as this strategy was uniquely designed to succeed independent of the need for federal legalization.”